高级检索
当前位置: 首页 > 详情页

Zebrafish facilitates drug screening: potential of 3-deoxy-andrographoside from Chuanxinlian ) as an anti-inflammatory agent

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ CSCD-C ◇ 卓越:梯队期刊

机构: [1]Third Level Research Laboratory of State Administration of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China. [2]Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Guangzhou 510515, China. [3]Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou 510632, China. [4]School of Pharmacy, Guangdong Pharmaceutical university, Guangzhou 510006, China. [5]Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China.
出处:
ISSN:

关键词: diterpenes lactones inflammation zebrafish myeloid differentiation factor 88 NF-kappa B STAT3 transcription factor

摘要:
To systematically evaluate the anti-inflammatory potential of diterpene lactones from Chuanxinlian () (AP).We firstly adopted zebrafish, a novel and ideal animal model for high-throughput drug screening, to investigate the anti-inflammatory activities of 17 diterpene lactones isolated from AP.The results showed that most of diterpene lactones displayed significant anti-inflammatory effects in lipopolysaccharide microinjection-, copper sulfate exposure- or tail transection-induced zebrafish inflammation models. Moreover, diterpene lactone 3-deoxy-andrographoside (AP-5) was firstly found to attenuate inflammatory responses, which was closely associated with the myeloid differentiation primary response 88/nuclear factor-kappa B and signal transducer and activator of transcription 3 pathways.Our research sheds light on the inestimable roles of zebrafish in high-throughput drug screening, elucidates the potent inhibitory effects of diterpene lactones against inflammation and indicates that AP-5 may serve as a potential alternative agent for the treatment of inflammatory diseases.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 全科医学与补充医学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 全科医学与补充医学
第一作者:
第一作者机构: [1]Third Level Research Laboratory of State Administration of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China. [2]Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Guangzhou 510515, China.
通讯作者:
通讯机构: [1]Third Level Research Laboratory of State Administration of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China. [2]Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Guangzhou 510515, China. [4]School of Pharmacy, Guangdong Pharmaceutical university, Guangzhou 510006, China. [5]Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China. [*1]Third Level Research Laboratory of State Administration of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China. [*2]School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号